U.S. Markets closed

Conatus Pharmaceuticals (CNAT) Crumbles: Stock Plunges by 18.7%

Zacks Equity Research

Conatus Pharmaceuticals Inc. (CNAT) saw a big move last session, as the company’s shares fell by nearly 19% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for CNAT as the stock is now up around 44% in the past one-month time frame.

Although this slump was obviously disappointing, the biotechnology company has seen 2 positive revisions and its current year loss consensus has narrowed down over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for CNAT. So make sure to keep an eye on this stock going forward to see if yesterday’s price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.

CNAT currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the Medical Products industry include Cardica Inc. (CRDC), ICU Medical, Inc. (ICUI) and NeuroMetrix Inc. (NURO). All the three stocks carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


CARDICA INC (CRDC): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

NEUROMETRIX INC (NURO): Free Stock Analysis Report

Zacks Investment Research